Trishia Frost, APRN
Family · Lincoln, NENPI 1417979774
Payments from drug & device makers
Across 138 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Astellas Pharma US Inc$711
- Novo Nordisk$226
- Pfizer$88
- Eisai Inc.$49
- AstraZeneca$29
- plus $299 from 17 others
What the payments were for
- Food & beverage$2,80797%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $1,504 |
| Astellas Pharma US Inc | 21 | $711 |
| Novo Nordisk | 14 | $226 |
| Pfizer | 6 | $88 |
| Eisai Inc. | 1 | $49 |
| AstraZeneca | 2 | $29 |
| Merck | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Exact Sciences | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| Bausch Health US, LLC | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Amgen | 1 | $15 |
| Ardelyx, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| GSK | 1 | $11 |
How this compares
$2,906 in reported general payments places this provider in the 85th percentile of 809 family providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $64,640 |
| JanuviaSitagliptin Phosphate | 55 | $46,120 |
| XareltoRivaroxaban | 51 | $36,736 |
| JardianceEmpagliflozin | 48 | $32,304 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $25,231 |
| FarxigaDapagliflozin Propanediol | 35 | $21,728 |
| EliquisApixaban | 37 | $21,121 |
| TradjentaLinagliptin | 12 | $17,969 |
| MyrbetriqMirabegron | 17 | $13,313 |
| Spiriva RespimatTiotropium Bromide | 21 | $11,484 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $8,125 |
| InvokanaCanagliflozin | 12 | $6,725 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $4,686 |
| Metformin Hcl | 181 | $3,944 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $226 | $64,64066 claims |
| MerckJanuvia | $28 | $46,12055 claims |
| AstraZenecaFarxiga, Symbicort | $29 | $29,85370 claims |
| GSKTrelegy Ellipta | $11 | $25,23138 claims |
| PfizerEliquis | $88 | $21,12137 claims |
| Astellas Pharma US IncMyrbetriq | $711 | $13,31317 claims |
| AbbVieSynthroid | $1,504 | $93611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 809 family providers in Nebraska.
Other family in Lincoln
- Mary MetzLincoln$13K
- Alyson FergusonLincoln$7K
- Mary GladeLincoln$7K
- Colleen CarpenterLincoln$5K
- Melany MurrayLincoln$5K
- Samantha NiceLincoln$5K
- Miranda PollmanLincoln$5K
- Marissa EbelLincoln$5K
- John GrandgenettLincoln$4K
- Chelsy BinkleyLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.